Amicus Moving on Phase II Data, Interest Ahead of Phase III Release in 4Q

Trading in Amicus Therapeutics (NASDAQ:FOLD) picked up considerably in the last few days, driving the stock up 19% to a high of $6.15 on Tuesday before the rally pulled back to more conservative levels around $5.70. On Thursday, however, FOLD is up 5% following the release of preliminary data from an ongoing Phase II Trial of AT2220 in the treatment of Pompe Disease.